SCHEMBL7080177

SCHEMBL7080177

CCOC(=O)c1cc(OCCCN(C=O)OC(C)(C)C)c2c(cnn2Cc2ccccc2)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EGFR P00533 5/20 0.41
ERBB2 P04626 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.36
F2RL3 Q96RI0 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CFTR P13569 1/20 0.36
MAPK1 P28482 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
TP53 P04637 2/20 0.35
MAPT P10636 2/20 0.35
CYP19A1 P11511 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14271500 0.83 EGFR (0.46) EGFRERBB2SMN1; SMN2KMT2APOLB
SCHEMBL4956996 0.81 EGFR (0.43) EGFRERBB2L3MBTL1CFTRTP53
SCHEMBL7086157 0.79 JMJD6 (0.34) SMN1; SMN2KMT2AMAPTKDM4EALDH1A1
SCHEMBL4957675 0.75 EGFR (0.49) EGFRERBB2SMN1; SMN2KMT2APOLB
SCHEMBL17582602 0.65 SMN1; SMN2 (0.56) EGFRERBB2SMN1; SMN2KMT2APOLB
SCHEMBL15920987 0.63 SMN1; SMN2 (0.61) SMN1; SMN2KMT2APOLBF2RL3MAPK1
SCHEMBL1242317 0.62 SMN1; SMN2 (0.49) EGFRERBB2SMN1; SMN2KMT2APOLB
SCHEMBL25604982 0.62 MAPK1 (0.52) EGFRERBB2SMN1; SMN2KMT2APOLB
SCHEMBL3265402 0.62 SMN1; SMN2 (0.60) SMN1; SMN2KMT2APOLBMAPK1TDP1
SCHEMBL21332805 0.61 SMN1; SMN2 (0.77) SMN1; SMN2KMT2APOLBMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296678-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY Bristol-Myers Squibb Pharma Company (US) 2003-04-02 EP disclosed
WO-2001098294-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-12-27 WO disclosed
EP-1140203-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS Du Pont Pharmaceuticals Company (US) 2001-10-10 EP disclosed
WO-2000035488-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 WO disclosed